Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erenumab in Chronic Cluster Headache
NCT04970355Phase 2
Key facts
- Status
- Completed
- Start
- Dec 2021
- Primary completion
- Sep 2023
- Countries
- 1
- Sponsor
- Charité – Universitätsmedizin Berlin
- Modality
- Monoclonal Antibodies
- Drugs
- erenumab
- Conditions
- Cluster Headache (CH)
01
Overview
Phase 2, randomised, double-blind trial of erenumab in Cluster Headache (CH), sponsored by Charité – Universitätsmedizin Berlin. Primary endpoint: Reduction of weekly cluster headache attack frequency from baseline at 6 weeks. Started Dec 2021; status: completed.
02
Design
- Study design
- RandomizedDouble-blind
03
Who it enrols
Adults aged 18-64 with chronic cluster headache for at least 12 months who have failed at least one approved prophylactic medication and experience at least 9 attacks per week.
04
Endpoints
Primary
Reduction of weekly cluster headache attack frequency from baseline
Beyond the preview
Go deeper on NCT04970355.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04970355.